Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 572

1.

Reduction of Pain During Flexible Cystoscopy: A Systematic Review and Meta-Analysis.

Raskolnikov D, Brown B, Holt SK, Ball AL, Lotan Y, Strope S, Schroeck F, Ullman R, Lipman R, Smith AB, Gore JL.

J Urol. 2019 Jun 20:101097JU0000000000000399. doi: 10.1097/JU.0000000000000399. [Epub ahead of print]

PMID:
31219763
2.

Evaluation of the UroVysion™ Test to Predict Recurrence and/or Progression of Disease After BCG for Primary High Grade Non-Muscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.

Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA.

J Urol. 2019 May 23:101097JU0000000000000355. doi: 10.1097/JU.0000000000000355. [Epub ahead of print]

PMID:
31120373
3.

Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.

Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y.

Eur Urol. 2019 May 16. pii: S0302-2838(19)30351-3. doi: 10.1016/j.eururo.2019.04.035. [Epub ahead of print]

4.

Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.

Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch CR, Steinberg GD, Svatek RS, Zwarthoff EC.

Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15. Review.

PMID:
31102625
5.

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA.

Eur Urol. 2019 May 12. pii: S0302-2838(19)30352-5. doi: 10.1016/j.eururo.2019.04.036. [Epub ahead of print]

PMID:
31092337
6.

Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.

Woldu SL, Moore JA, Ci B, Freifeld Y, Clinton TN, Aydin AM, Singla N, Laura-Maria K, Hutchinson RC, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Xie Y, Bagrodia A.

Eur Urol Oncol. 2018 Aug;1(3):242-251. doi: 10.1016/j.euo.2018.04.005. Epub 2018 Jun 6.

PMID:
31058267
7.

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.

Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.

Nat Rev Urol. 2019 Jun;16(6):377-386. doi: 10.1038/s41585-019-0184-4. Review.

PMID:
31019310
8.

Molecular Characterization of Neuroendocrine-like Bladder Cancer.

Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC.

Clin Cancer Res. 2019 Apr 5. doi: 10.1158/1078-0432.CCR-18-3558. [Epub ahead of print]

PMID:
30952638
9.

Progress toward a Nordic standard for the investigation of hematuria: 2019.

Lotan Y.

Scand J Urol. 2019 Feb;53(1):8. doi: 10.1080/21681805.2019.1594581. Epub 2019 Apr 2. No abstract available.

PMID:
30935284
10.

Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.

Owyong M, Lotan Y, Kapur P, Panwar V, McKenzie T, Lee TK, Zi X, Martin JW, Mosbah A, Abol-Enein H, Ghoneim M, Youssef RF.

Urol Oncol. 2019 Jul;37(7):478-484. doi: 10.1016/j.urolonc.2019.02.017. Epub 2019 Mar 23.

PMID:
30910351
11.

Predicting recurrence in patients with localised renal cell carcinoma after nephrectomy.

Lotan Y, Margulis V.

Lancet Oncol. 2019 Apr;20(4):473-475. doi: 10.1016/S1470-2045(19)30024-5. Epub 2019 Mar 14. No abstract available.

PMID:
30880069
12.

Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer.

Vantaku V, Dong J, Ambati CR, Perera D, Donepudi SR, Amara CS, Putluri V, Ravi SS, Robertson MJ, Piyarathna DWB, Villanueva M, von Rundstedt FC, Karanam B, Ballester LY, Terris MK, Bollag RJ, Lerner SP, Apolo AB, Villanueva H, Lee M, Sikora AG, Lotan Y, Sreekumar A, Coarfa C, Putluri N.

Clin Cancer Res. 2019 Jun 15;25(12):3689-3701. doi: 10.1158/1078-0432.CCR-18-1515. Epub 2019 Mar 7.

PMID:
30846479
13.

Delivery of Bottled Water to Women With Recurrent Urinary Tract Infections: Why in Bulgaria?-Reply.

Hooton TM, Vecchio M, Lotan Y.

JAMA Intern Med. 2019 Mar 1;179(3):449. doi: 10.1001/jamainternmed.2018.7977. No abstract available.

PMID:
30830193
14.

Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer.

Stovsky M, Klein EA, Chait A, Manickam K, Stephenson AJ, Wagner M, Dineen M, Lotan Y, Partin A, Baniel J, Kestranek A, Gawande P, Boris Zaslavsky.

J Urol. 2019 Jun;201(6):1115-1120. doi: 10.1097/JU.0000000000000185.

PMID:
30810464
15.

Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts.

Tse J, Ghandour R, Singla N, Lotan Y.

Int J Mol Sci. 2019 Feb 13;20(4). pii: E793. doi: 10.3390/ijms20040793. Review.

16.

Recent advances in the metabolomic study of bladder cancer.

Amara CS, Vantaku V, Lotan Y, Putluri N.

Expert Rev Proteomics. 2019 Apr;16(4):315-324. doi: 10.1080/14789450.2019.1583105. Epub 2019 Feb 26.

PMID:
30773067
17.

Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study.

Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM.

World J Urol. 2019 Feb 13. doi: 10.1007/s00345-019-02678-x. [Epub ahead of print]

PMID:
30759271
18.

Diagnostic Performance of Prospectively Assigned Likert Scale Scores to Determine Extraprostatic Extension and Seminal Vesicle Invasion With Multiparametric MRI of the Prostate.

Freifeld Y, Diaz de Leon A, Xi Y, Pedrosa I, Roehrborn CG, Lotan Y, Francis F, Costa DN.

AJR Am J Roentgenol. 2019 Mar;212(3):576-581. doi: 10.2214/AJR.18.20320. Epub 2018 Dec 27.

PMID:
30589381
19.

Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.

Valenberg FJPV, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK, Stenzl A, Danella JF, Shepard B, Cline KJ, Williams MB, Montgomery S, David RD, Harris R, Klein EW, Bradford TJ, Wolk FN, Westenfelder KR, Trainer AF, Richardson TA, Egerdie RB, Goldfarb B, Zadra JA, Ge S, Zhao S, Simon IM, Campbell SA, Rhees B, Bates MP, Higuchi RG, Witjes JA.

Eur Urol. 2019 May;75(5):853-860. doi: 10.1016/j.eururo.2018.11.055. Epub 2018 Dec 12.

PMID:
30553612
20.

Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.

Freifeld Y, Xi Y, Passoni N, Woldu S, Hornberger B, Goldberg K, Bagrodia A, Raj G, Margulis V, Cadeddu JA, Lotan Y, Francis F, Pedrosa I, G Roehrborn C, Costa DN.

Urol Oncol. 2019 Jan;37(1):57-62. doi: 10.1016/j.urolonc.2018.10.009. Epub 2018 Nov 13.

PMID:
30446460
21.

A Festschrift in Honor of Edward M. Messing, MD, FACS.

Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D.

Bladder Cancer. 2018 Oct 3;4(Suppl 1):S1-S43. doi: 10.3233/BLC-189037. No abstract available.

22.

Validating the predictors of outcomes after radical cystectomy for bladder cancer.

Woldu SL, Sanli O, Clinton TN, Lotan Y.

Cancer. 2019 Jan 15;125(2):223-231. doi: 10.1002/cncr.31799. Epub 2018 Oct 6.

PMID:
30291813
23.

Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial.

Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, Lotan Y.

JAMA Intern Med. 2018 Nov 1;178(11):1509-1515. doi: 10.1001/jamainternmed.2018.4204.

PMID:
30285042
24.

Effect of blue-light cystoscopy on contemporary performance of urine cytology.

Freifeld Y, Lotan Y.

BJU Int. 2018 Oct 3. doi: 10.1111/bju.14574. [Epub ahead of print]

PMID:
30281893
25.

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.

Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF.

Eur Urol. 2018 Dec;74(6):784-795. doi: 10.1016/j.eururo.2018.09.001. Epub 2018 Sep 26.

PMID:
30268659
26.

Molecular markers in bladder cancer.

Soria F, Krabbe LM, Todenhöfer T, Dobruch J, Mitra AP, Inman BA, Gust KM, Lotan Y, Shariat SF.

World J Urol. 2019 Jan;37(1):31-40. doi: 10.1007/s00345-018-2503-4. Epub 2018 Sep 26. Review.

27.

Seniority of primary care physicians is associated with a decrease in PSA ordering habits in the years surrounding the United States Preventative Services Task Force recommendation against PSA screening.

Hutchinson R, Singla N, Akhtar A, Haridas J, Bhat D, Roehrborn C, Lotan Y.

Urol Oncol. 2018 Nov;36(11):500.e21-500.e27. doi: 10.1016/j.urolonc.2018.07.011. Epub 2018 Sep 18.

PMID:
30241954
28.

Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study.

Woldu SL, Matulay JT, Clinton TN, Singla N, Freifeld Y, Sanli O, Krabbe LM, Hutchinson RC, Lotan Y, Hammers H, Hannan R, Brugarolas J, Bagrodia A, Margulis V.

Clin Genitourin Cancer. 2018 Dec;16(6):e1221-e1235. doi: 10.1016/j.clgc.2018.08.001. Epub 2018 Aug 25.

PMID:
30217763
29.

Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice?

Soria F, D'Andrea D, Pohar K, Shariat SF, Lotan Y.

Curr Opin Urol. 2018 Nov;28(6):577-583. doi: 10.1097/MOU.0000000000000545.

PMID:
30157039
30.

Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo.

Courtney KD, Bezwada D, Mashimo T, Pichumani K, Vemireddy V, Funk AM, Wimberly J, McNeil SS, Kapur P, Lotan Y, Margulis V, Cadeddu JA, Pedrosa I, DeBerardinis RJ, Malloy CR, Bachoo RM, Maher EA.

Cell Metab. 2018 Nov 6;28(5):793-800.e2. doi: 10.1016/j.cmet.2018.07.020. Epub 2018 Aug 23.

PMID:
30146487
31.

Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study.

Smith AB, Daneshmand S, Patel S, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Taylor J, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS, Lotan Y; Flexible Blue Light Study Group Collaborators.

BJU Int. 2019 Jan;123(1):35-41. doi: 10.1111/bju.14481. Epub 2018 Aug 11.

PMID:
29979488
32.

An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.

Soria F, Droller MJ, Lotan Y, Gontero P, D'Andrea D, Gust KM, Rouprêt M, Babjuk M, Palou J, Shariat SF.

World J Urol. 2018 Dec;36(12):1981-1995. doi: 10.1007/s00345-018-2380-x. Epub 2018 Jun 21. Review.

33.

The use of blue light flexible cystoscopy with hexaminolevulinate & the diagnosis of bladder cancer.

Clinton TN, Lotan Y.

Future Oncol. 2018 Nov;14(27):2805-2810. doi: 10.2217/fon-2018-0328. Epub 2018 Jun 21. Review.

PMID:
29925279
34.

Editorial Comment.

Lotan Y.

Urology. 2018 Aug;118:111-112. doi: 10.1016/j.urology.2018.04.041. Epub 2018 Jun 6. No abstract available.

PMID:
29886039
35.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC.

World J Urol. 2019 Jan;37(1):165-172. doi: 10.1007/s00345-018-2361-0. Epub 2018 Jun 7.

PMID:
29882105
36.

Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort.

Martin JW, Vernez SL, Lotan Y, Abdelhalim A, Dutta R, Shokeir A, Abol-Enein H, Mosbah A, Ghoneim M, Youssef RF.

World J Urol. 2018 Nov;36(11):1835-1843. doi: 10.1007/s00345-018-2331-6. Epub 2018 May 14.

PMID:
29761225
37.

Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.

Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V.

Urol Oncol. 2018 Jul;36(7):343.e1-343.e8. doi: 10.1016/j.urolonc.2018.04.004. Epub 2018 May 7.

PMID:
29748098
38.

Cost-effectiveness of antimicrobial prophylaxis for children in the RIVUR trial.

Palmer LS, Seideman CA, Lotan Y.

World J Urol. 2018 Sep;36(9):1441-1447. doi: 10.1007/s00345-018-2302-y. Epub 2018 Apr 30.

PMID:
29707736
39.

Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures.

Woldu SL, Hutchinson RC, Singla N, Hornberger B, Roehrborn CG, Lotan Y.

Urol Pract. 2018 Mar;5(2):124-131. doi: 10.1016/j.urpr.2017.03.002. Epub 2017 Mar 18.

40.

Re: Who Should be Investigated for Hematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients.

Lotan Y.

Eur Urol. 2018 Jul;74(1):15-16. doi: 10.1016/j.eururo.2018.03.019. Epub 2018 Apr 4. No abstract available.

PMID:
29625759
41.

Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Lotan Y, Woldu SL, Sanli O, Black P, Milowsky MI.

BJU Int. 2018 Sep;122(3):434-440. doi: 10.1111/bju.14220. Epub 2018 Apr 24.

PMID:
29603871
42.

Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer.

Kittler R, Shiang C, Hutchinson R, Kollipara RK, Kapur P, Franto F, Lotan Y.

Oncotarget. 2018 Jan 6;9(10):9415-9424. doi: 10.18632/oncotarget.24072. eCollection 2018 Feb 6.

43.

Diagnostic Utility of a Likert Scale Versus Qualitative Descriptors and Length of Capsular Contact for Determining Extraprostatic Tumor Extension at Multiparametric Prostate MRI.

Costa DN, Passoni NM, Leyendecker JR, de Leon AD, Lotan Y, Roehrborn CG, Otero-Muinelo S, Grewal H, Xi Y, Francis F, Rofsky NM, Pedrosa I.

AJR Am J Roentgenol. 2018 May;210(5):1066-1072. doi: 10.2214/AJR.17.18849. Epub 2018 Feb 28.

PMID:
29489410
44.

Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer.

Masuda N, Ogawa O, Park M, Liu AY, Goodison S, Dai Y, Kozai L, Furuya H, Lotan Y, Rosser CJ, Kobayashi T.

Oncotarget. 2018 Jan 3;9(6):7101-7111. doi: 10.18632/oncotarget.23872. eCollection 2018 Jan 23.

45.

Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test.

Zhang S, Wang Y, Bondaruk J, Majewski T, Yao H, Lee S, Lee JG, Cogdell D, Lotan Y, Dinney C, Wei P, Baggerly K, Czerniak B.

Eur Urol Focus. 2018 Feb 7. pii: S2405-4569(18)30018-X. doi: 10.1016/j.euf.2018.01.017. [Epub ahead of print]

PMID:
29428551
46.

Current approaches for identifying high-risk non-muscle invasive bladder cancer.

Sanli O, Lotan Y.

Expert Rev Anticancer Ther. 2018 Mar;18(3):223-235. doi: 10.1080/14737140.2018.1432358. Epub 2018 Jan 31. Review.

PMID:
29359984
47.

Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis.

Woldu SL, Ci B, Hutchinson RC, Krabbe LM, Singla N, Passoni NM, Clinton TN, Raj GV, Miller DS, Sagalowsky AI, Lotan Y, Xie Y, Margulis V, Bagrodia A.

Urol Oncol. 2018 Apr;36(4):159.e7-159.e17. doi: 10.1016/j.urolonc.2017.12.001. Epub 2017 Dec 26.

PMID:
29288008
48.

Advancements in optical techniques and imaging in the diagnosis and management of bladder cancer.

Rose TL, Lotan Y.

Urol Oncol. 2018 Mar;36(3):97-102. doi: 10.1016/j.urolonc.2017.11.014. Epub 2017 Dec 26. Review.

PMID:
29288006
49.

Tissue-based biomarkers in prostate cancer.

Clinton TN, Bagrodia A, Lotan Y, Margulis V, Raj GV, Woldu SL.

Expert Rev Precis Med Drug Dev. 2017;2(5):249-260. doi: 10.1080/23808993.2017.1372687. Epub 2017 Sep 5.

50.

Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.

Xylinas E, Kent M, Dabi Y, Rieken M, Kluth LA, Al Hussein Al Awamlh B, Ouzaid I, Pycha A, Comploj E, Svatek RS, Lotan Y, Karakiewicz PI, Holmang S, Shariat SF.

Urol Oncol. 2018 Mar;36(3):89.e1-89.e5. doi: 10.1016/j.urolonc.2017.11.010. Epub 2017 Dec 6.

PMID:
29221642

Supplemental Content

Support Center